NEW YORK – Treatment with afatinib (Boehringer Ingelheim's Gilotrif) followed by osimertinib (AstraZeneca's Tagrisso) appears to extend survival in patients with advanced, EGFR-mutated non-small cell lung cancer who have become resistant to first-line afatinib, according to a study published in Future Medicine last week.